Colak et al. documented significantly reduced erythrocyte SOD1 activity and plasma total antioxidative status (TAS) in patients with type 2 diabetes and CVD compared to healthy individuals [77]. This evidence concerns the gene SOD1 and type 2 diabetes mellitus.